SKIP TO
CONTENT
Six Flags Entertainment Securities Fraud Investigation
Investigation Deadline:
January 5, 2026
featured news
October 15, 2014
General
Pennsylvania Appellate Court Considers Confidential Nature of Qui Tam Actions in Light of Insurance Policy
In the corporate world, companies often take out extensive insurance policies to protect against the inevitable financial harms following a civil lawsuit. Much like any other insurance policy, the insurer will usually include language in the policy terms excluding coverage for any pending lawsuits filed or commenced prior to the […]
October 14, 2014
General
Shire Pharmaceuticals to Pay $56 Million to Settle False Claims Act Allegations
According to a recent announcement by the Department of Justice, Shire Pharmaceuticals has agreed to pay $56 million to settle claims it fraudulently marketed the popular attention-deficit drug Adderall and thereafter submitted claims to U.S. government healthcare programs for reimbursement. The allegations differ from the oft-cited problem of “off-label marketing,” […]
October 13, 2014
General
CVS Caremark Corporation Settles False Claims Act Allegations for $6 Million
In several prior posts, we have discussed the ongoing battle against “reverse false claims” involving Medicare and Medicaid patients. In general, a reverse false claim occurs when a healthcare provider or government contractor receives overpayment for an invoice and knowingly fails to issue a refund or reimbursement to the government. […]
October 10, 2014
General
SEC Announces $50 Million Whistleblower Award
In light of the 2008 financial crisis – which was propelled primarily by corporate misconduct and serious Wall Street delinquency – the 2010 Dodd-Frank Act was created in order to not only police investor transgressions but to incentivize those with knowledge of possible securities fraud to come forward and report […]
October 8, 2014
General
Novartis Pharmaceuticals to Face Possible False Claims Act Liability for Kickbacks
Swiss-based Novartis Pharmaceuticals has been subjected to possible liability under the False Claims Act – and a federal judge in New York recently concluded the case may continue. In U.S. ex rel. Bilotti v. Novartis Pharmaceuticals Corp., a whistleblower brought to light several issues involving the drug maker, most notably […]
Contact UsFree Case Evaluation
"*" indicates required fields
By clicking SUBMIT you agree to our Terms of Use and Privacy Policy and you are providing express consent to receive communications from Berger Montague via calls, emails, and/or text messages.
featured investigations
$2.4B+
in 2025 post-trial judgments
$50B+
in Settlements & Verdicts
55+
Years of Experience With High-Profile Cases
100+
Attorneys Protecting Your Rights
20+
Years Ranked as Top Law Firm by Chambers USA
50
States in Which The Firm Has Successfully Litigated
On the Cutting Edge of the Profession
Legal Intelligencer